Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
There have been large buys happening everyday recently, but SP is fairly steady. Seems like the MMs have stocks in hand from at least one seller, but there is definitely another buyer quietly accumulating. Hopefully we will see some TR1s in the next few days to reveal everything.
There were actually two 650k buys today, someone is really accumulating on the cheap. Interesting that we are still at placing price, and the market has no expectations whatsoever from the Star trial. Hope we can give a big surprise result and throw our hat in the ring as well, especially after Boris's therapeutics announcement this evening to find an anti covid pill by autumn.
There is also another trade showing as -2m at the same time. I am guessing it means the original trade did not actually happen? Would have been nice to see some big buying and SP support as at the moment it looks like the market has next to zero expectation of any positive result emerging from the Star trial. Let's hope for a big surprise in Q2.
Thanks MM, the refund has also come through for me this morning.
Matterhorn from what I can understand the protocol for phase 2 for both infused and non infused agent is suggested to be the same. It's just the phase 3 design which is not yet defined. It's says this on page 14.
For non-infused agents, the same phase II study will be
undertaken as for infused agents. However, the design of the
phase III evaluation for non-infused agents will be developed in a
subsequent version of the protocol. Once developed, non-
infused agents may also enter directly into phase III base d on TOC assessments.
The 28 days reference is 28 days after the last of the 220 patients have been recruited rather than the first patient.
This is from the Activ 2 master protocol.
"For each infused agent, an interim analysis will be conducted when the 220
participants assigned to the agent or concurrent placebo in phase II evaluation have
data available through to day 28 of follow-up. This interim analysis will be used to
assess whether study-defined “graduation” criteria have been met so that the
agent may graduate to phase III evaluation. The graduation criteria are described
further below."
My best guess news on on whether the treatment works is still a few weeks away, as it needs all 220 patients recruited first plus 28 days of follow up.
What I would expect news to first land anytime on is an interim one on the following on safety concerns only.
"Phase II Early Termination
During the phase II evaluation, there will be review of interim safety results by an
independent Data and Safety Monitoring Board (DSMB) when 50% of the planned
phase II enrollment for an investigational agent have completed day 14
evaluations. The DSMB may recommend early termination of randomization to a
particular investigational agent if there are safety concerns."
For anyone interested the master protocol is here.
https://fnih.org/sites/default/files/final/pdf/Protocol-activ-2-A5401-version3-dated12.22.20.pdf
Has anyone received their refund on their unallocated open offer application? The new shares have been added but I am yet to see the cash refund on my trading account with Halifax.
Apologies if already posted, am not very active in following the BB discussions these days, but found this recent article giving further evidence that interferons are the key for developing effective Covid 19 treatments.
It's a small clinical trial using Interferon alfa-2b which showed it was significantly effective in improving outcomes against Covid 19. Hopefully bodes well for SNGs interferon trial.
https://www.sciencedirect.com/science/article/pii/S1201971221002320
Definitely a bit disappointed with this and doesn't really convey a good message to the market. Might have been better to not have taken part at all as I can see it's likely to have affected sentiments negatively looking at the SP movements since the RNS came out
I am still unable to see the allocated shares in my Halifax account, nor have I received any refund. I can just see the initial applied shares separately with 0 value. Thought today was the day when the shares would be admitted for trading.
With the level of oversubscription I see a very strong support at 8p now, so dipping below it is likely to only happen if the news from the covid trial is not positive.
So it means 7.1m excess shares were available after basic entitlement to PIs, and application received was for 14.4m excess shares. So anyone applying for excess shares would receive about half of their excess application?
Pleasantly surprised that the PI open offer was heavily oversubscribed.
I guess what was showing on my Halifax account earlier was just my initial applied shares rather than what I have actually now received.
Seems like I have got the full allotment as I can see the new shares on Halifax including the extra ones I had asked for. Previously I could not see this. Perhaps the PI open offer was also under subscribed as would not have got the full extra allotment otherwise. Not sure if others can also see theirs in their trading account?
Had got a big shock initially when I opened my trading account this afternoon as the SP is showing as 1p with a big loss, so thought some news has been released and the price has completely crashed, before realising that it was just the open offer allotment shown separately and not available for trading..lol
A small reluctant top-up from me this morning to further lower my average by a few pences. Hopefully this is somewhere near bottom, but if not have kept a little more funds aside for one last attempt.
I have just tried to dig a bit on take up rates for the trial. The NHS publishes statistics on hospital admissions.
https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/
Looking at the statistics for the University Hospitals Dorset Trust hospitals, there have been 346 Covid 19 admissions to the 3 hospitals in Poole, Bournemouth and Christchurch which make up the trust between 1st Feb and 21st Feb.
I have no idea about the sizes of the 3 hospitals, but let's assume they are all equal in size so we have about 220 admissions to Bournemouth and Christchurch between 1st and 21st Feb.
If we had 12 recruited until say a couple of days back, it roughly suggests about 5% of the patients agreed to take part in the trial based on the estimated hospital admissions here.
I just hope we have at least 10 to 15 hospitals already in the trial if the 5% take up rate might also apply across other sites. This is to stand a chance of completing the trial in the next few weeks in light of the falling hospital admission rates.
Isn't this the actual page for the trial? https://clinicaltrials.gov/ct2/show/NCT04732949
This one only has 3 hospitals listed. Bournemouth and Christchurch are of course not listed here.